Literature DB >> 20669299

LRRK2 variation and Parkinson's disease in African Americans.

Owen A Ross1, Greggory J Wilhoite, Justin A Bacon, Alexandra Soto-Ortolaza, Jennifer Kachergus, Stephanie A Cobb, Andreas Puschmann, Carles Vilariño-Güell, Matthew J Farrer, Neill Graff-Radford, James F Meschia, Zbigniew K Wszolek.   

Abstract

The global impact of LRRK2 mutations is yet to be realized with a lack of studies in specific ethnic groups, including those of Asian and African descent. Herein, we investigated the frequency of common LRRK2 variants by complete exon sequencing in a series of publicly available African American Parkinson's disease patients. Our study identified three novel synonymous exonic variants and 13 known coding variations; however, there did not appear to be any frequent (>5%) pathogenic mutations. Given the ethnic-specific LRRK2 variation previously identified in PD further studies in under-represented populations are warranted.
© 2010 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20669299      PMCID: PMC2939165          DOI: 10.1002/mds.23163

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  14 in total

1.  A common missense variant in the LRRK2 gene, Gly2385Arg, associated with Parkinson's disease risk in Taiwan.

Authors:  Alessio Di Fonzo; Yah-Huei Wu-Chou; Chin-Song Lu; Marina van Doeselaar; Erik J Simons; Christan F Rohé; Hsiu-Chen Chang; Rou-Shayn Chen; Yi-Hsin Weng; Nicola Vanacore; Guido J Breedveld; Ben A Oostra; Vincenzo Bonifati
Journal:  Neurogenetics       Date:  2006-04-22       Impact factor: 2.660

2.  Screening for Lrrk2 G2019S and clinical comparison of Tunisian and North American Caucasian Parkinson's disease families.

Authors:  Lianna Ishihara; Rachel A Gibson; Liling Warren; Rim Amouri; Kelly Lyons; Catherine Wielinski; Christine Hunter; Jina E Swartz; Ramu Elango; P Anthony Akkari; David Leppert; Linda Surh; Kevin H Reeves; Siwan Thomas; Leigh Ragone; Nobutaka Hattori; Rajesh Pahwa; Joseph Jankovic; Martha Nance; Alan Freeman; Neziha Gouider-Khouja; Mounir Kefi; Mourad Zouari; Samia Ben Sassi; Samia Ben Yahmed; Ghada El Euch-Fayeche; Lefkos Middleton; David J Burn; Ray L Watts; Faycal Hentati
Journal:  Mov Disord       Date:  2007-01       Impact factor: 10.338

3.  LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs.

Authors:  Suzanne Lesage; Alexandra Dürr; Meriem Tazir; Ebba Lohmann; Anne-Louise Leutenegger; Sabine Janin; Pierre Pollak; Alexis Brice
Journal:  N Engl J Med       Date:  2006-01-26       Impact factor: 91.245

4.  LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews.

Authors:  Laurie J Ozelius; Geetha Senthil; Rachel Saunders-Pullman; Erin Ohmann; Amanda Deligtisch; Michele Tagliati; Ann L Hunt; Christine Klein; Brian Henick; Susan M Hailpern; Richard B Lipton; Jeannie Soto-Valencia; Neil Risch; Susan B Bressman
Journal:  N Engl J Med       Date:  2006-01-26       Impact factor: 91.245

Review 5.  An analysis of genetic studies of Parkinson's disease in Africa.

Authors:  Njideka U Okubadejo
Journal:  Parkinsonism Relat Disord       Date:  2007-09-18       Impact factor: 4.891

6.  Haploview: Visualization and analysis of SNP genotype data.

Authors:  Jeffrey C Barrett
Journal:  Cold Spring Harb Protoc       Date:  2009-10

7.  Lrrk2 pathogenic substitutions in Parkinson's disease.

Authors:  Ignacio F Mata; Jennifer M Kachergus; Julie P Taylor; Sarah Lincoln; Jan Aasly; Timothy Lynch; Mary M Hulihan; Stephanie A Cobb; Ruey-Meei Wu; Chin-Song Lu; Carlos Lahoz; Zbigniew K Wszolek; Matthew J Farrer
Journal:  Neurogenetics       Date:  2005-09-17       Impact factor: 2.660

8.  Clinical features of Parkinson disease patients with homozygous leucine-rich repeat kinase 2 G2019S mutations.

Authors:  Lianna Ishihara; Liling Warren; Rachel Gibson; Rim Amouri; Suzanne Lesage; Alexandra Dürr; Meriem Tazir; Zbigniew K Wszolek; Ryan J Uitti; William C Nichols; Alida Griffith; Nobutaka Hattori; David Leppert; Ray Watts; Cyrus P Zabetian; Tatiana M Foroud; Matthew J Farrer; Alexis Brice; Lefkos Middleton; Faycal Hentati
Journal:  Arch Neurol       Date:  2006-09

9.  Study of familial Parkinson's disease in Russia, Uzbekistan, and Zambia.

Authors:  M Atadzhanov; A Zumla; P Mwaba
Journal:  Postgrad Med J       Date:  2005-02       Impact factor: 2.401

10.  Lrrk2 R1441C parkinsonism is clinically similar to sporadic Parkinson disease.

Authors:  K Haugarvoll; R Rademakers; J M Kachergus; K Nuytemans; O A Ross; J M Gibson; E-K Tan; C Gaig; E Tolosa; S Goldwurm; M Guidi; G Riboldazzi; L Brown; U Walter; R Benecke; D Berg; T Gasser; J Theuns; P Pals; P Cras; P Paul De Deyn; S Engelborghs; B Pickut; R J Uitti; T Foroud; W C Nichols; J Hagenah; C Klein; A Samii; C P Zabetian; V Bonifati; C Van Broeckhoven; M J Farrer; Z K Wszolek
Journal:  Neurology       Date:  2008-03-12       Impact factor: 9.910

View more
  3 in total

Review 1.  Parkinson disease in the elderly adult.

Authors:  Allison W Willis
Journal:  Mo Med       Date:  2013 Sep-Oct

2.  Fine-mapping of the non-coding variation driving the Caucasian LRRK2 GWAS signal in Parkinson's disease.

Authors:  Michael G Heckman; Catherine Labbé; Ana L Kolicheski; Alexandra I Soto-Beasley; Ronald L Walton; Rebecca R Valentino; Emily R Brennan; Patrick W Johnson; Saurabh Baheti; Vivekananda Sarangi; Yingxue Ren; Ryan J Uitti; Zbigniew K Wszolek; Owen A Ross
Journal:  Parkinsonism Relat Disord       Date:  2021-01-11       Impact factor: 4.402

3.  Low Levels of LRRK2 Gene Expression are Associated with LRRK2 SNPs and Contribute to Parkinson's Disease Progression.

Authors:  Selma Yılmazer; Esin Candaş; Gençer Genç; Merve Alaylıoğlu; Büşra Şengül; Ayşegül Gündüz; Hülya Apaydın; Güneş Kızıltan; Sibel Ertan; Erdinç Dursun; Duygu Gezen-Ak
Journal:  Neuromolecular Med       Date:  2020-10-04       Impact factor: 3.843

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.